Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.
Tandem Diabetes Care reports developments in automated insulin delivery and diabetes technology. The company manufactures and sells pump systems including Tandem Mobi and the t:slim X2 insulin pump, both powered by Control-IQ+ advanced hybrid closed-loop technology. News commonly covers FDA clearances, pump and mobile-app compatibility, continuous glucose monitoring integrations, and product portfolio updates for people with diabetes.
Company updates also address quarterly and annual operating results, worldwide and U.S. sales trends, pump shipments, gross margin, financial guidance, reimbursement-model changes, investor conference presentations, and capital actions such as convertible debt financing.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will release its third quarter 2021 results on November 3, 2021, after market close. A conference call is scheduled for 4:30 PM ET to discuss the financial and operational outcomes. Interested parties can access the call via toll-free and international dial-in numbers or through a webcast link provided in the release. The event will be archived for 30 days on Tandem's Investor Center website.
Tandem Diabetes Care (NASDAQ: TNDM) has announced upcoming presentations at several virtual investor conferences. These include:
- Wells Fargo 2021 Virtual Health Care Conference on September 9, 2021, at 4:35 PM ET
- Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 3:30 PM ET
- Baird 2021 Global Healthcare Conference on September 15, 2021, at 12:50 PM ET
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, at 4:35 PM ET
Live webcasts will be available, with recordings accessible for 30 days on the company’s investor website.
Tandem Diabetes Care (NASDAQ: TNDM) reported strong financial results for Q2 2021, with worldwide pump shipments up 81% to 33,817 units and sales rising 58% to $172.1 million. The gross margin increased to 54%, while operating income turned positive at $5.4 million. The company added 40% domestic pump shipments and 233% international growth, pushing adjusted EBITDA to $23.8 million. Cash reserves reached $545.3 million. Revised guidance for 2021 estimates sales between $670 million and $685 million, reflecting a growth of 34-37% year-over-year.
Tandem Diabetes Care (NASDAQ: TNDM) will present a company update at the UBS Genomics 2.0 and Medtech Innovations Summit on August 12, 2021, at 2:00 PM ET. The presentation will be available via a live webcast, with an archived recording accessible for 30 days thereafter. The link can be found on the Investor Center section of Tandem's website. Tandem focuses on improving the lives of people with diabetes through innovative medical devices, including their flagship product, the t:slim X2 insulin pump, which supports remote software updates and features integrated glucose monitoring.
Tandem Diabetes Care (NASDAQ: TNDM) is set to release its second quarter 2021 results on August 4, 2021, after market close. A conference call will follow at 4:30 PM ET to discuss financial and operational outcomes. Investors can join via a toll-free number or webcast. The company focuses on innovative insulin delivery solutions, with its flagship product being the t:slim X2™ insulin pump, which supports remote updates and integrated glucose monitoring.
Tandem Diabetes Care (NASDAQ: TNDM) recently showcased positive real-world data regarding its t:slim X2 insulin pump with Control-IQ technology at the American Diabetes Association's 81st Scientific Sessions. The findings indicate statistically significant glycemic improvements and enhanced quality of life for users, including diverse populations. Notably, disparities in glycemic outcomes by ethnicity were observed, but improvements were consistent across all groups. Key presentations highlighted the efficacy of Control-IQ in managing diabetes and its impact on users' daily lives.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) showcased successful real-world use data of its t:slim X2™ insulin pump with Control-IQ™ technology at the ATTD conference. Over 9,000 users experienced significant improvements in time in range (TIR) for diabetes management over 12 months. Dr. Jordan Pinsker emphasized the technology's real-world effectiveness and the positive impact on patients' quality of life. Additional studies indicated a median TIR of 73.6%, with high automation rates and low incidences of hypoglycemia, reflecting strong performance and user satisfaction with the device.
Tandem Diabetes Care, Inc. (TNDM) reported a strong first quarter of 2021, with worldwide pump shipments increasing 46% to 25,352 units and sales rising 44% to $141 million, compared to Q1 2020. Gross profit improved to $73.3 million, and Adjusted EBITDA reached $13.2 million. The company's net loss narrowed to $5 million from $14.9 million year-over-year. Tandem updated its 2021 sales guidance, now estimating $625-$640 million, marking a growth of 25-28% year-over-year. International sales are projected at $125-$130 million, reflecting a 50-56% increase.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced its participation in three upcoming virtual investor conferences. Management will provide updates during:
- BofA Securities 2021 Virtual Health Care Conference on May 12, 2021, at 5:00 PM ET
- Berenberg Conference USA 2021 on May 18, 2021, at 3:00 PM ET
- UBS Global Healthcare Virtual Conference on May 24, 2021, at 12:00 PM ET
These presentations will be webcast live and available for 30 days on the company's Investor Center website.
CeQur has completed an oversubscribed $115 million equity financing to support commercial plans for its insulin-delivery device, CeQur Simplicity. The funds will enhance market development, initiate a phased launch in 2021, and scale manufacturing. CeQur Simplicity is FDA cleared and CE-marked, designed to replace multiple daily injections for over 3 million Americans. Clinical studies show significant improvement in insulin regimen adherence and glycemic control. The device targets a $7.5 billion U.S. market, aiming to ease insulin delivery for diabetes patients globally.